Thrombospondin-1 and Transforming Growth Factor Beta-1 Upregulate Plasminogen Activator Inhibitor Type 1 in Pancreatic Cancer

Journal of Gastrointestinal Surgery

Volumn 3, Issue 4, 1999, Pages 411-417

  Albo, Daniel ^a   Berger, David H ^a   Vogel, Jon ^a   Tuszynski, George P ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Pancreatic neoplasms; Plasminogen activator inhibitor; Thrombospondin 1; Transforming growth factor beta 1; Urokinase plasminogen activator

Indexed keywords

CANCER ANTIBODY; CD36 ANTIGEN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UROKINASE;

ARTICLE; CANCER INVASION; CELL CULTURE; DOSE RESPONSE; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PANCREAS TUMOR; STATISTICAL MODEL; STATISTICS; UPREGULATION;

ANTIBODIES, NEOPLASM; ANTIGENS, CD36; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LINEAR MODELS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; STATISTICS; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; UP-REGULATION; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033155804     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(99)80058-4     Document Type: Article

References (40)

1. Kwaan HC. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 1992;11:291-311.
2. Testa JE, Quigley JP. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev 1990;9:353-367.
3. Blasi F, Behrendt N, Cubellis MV, Ellis V, Lund LR, Masucci MT. The urokinase receptor and regulation of cell surface plasminogen activation. Cell Differ Dev 1990;32:247-254.
4. Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor bound urokinase. A. kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991;226:12752-12758.
5. Blasi F. Molecular mechanisms of protease-mediated tumor invasiveness. J Surg Oncol Suppl 1993;3:21-23.
6. Blasi F. Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 1993;15:105-111.
7. Hosokawa T, Muraishi A, Rothman V, Papale M, Tuszynski GP. The effect of thrombospondin on invasion of fibrin gels by human A549 lung carcinoma. Oncol Res 1993;5:183-189.
8. Albo D, Arnoletti JP, Castiglioni A, Granick MS, Solomon MP, Rothman VL, Tuszynski GP. Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro. Biochem Biophys Res Commun 1994;203:857-865.
9. Albo D, Berger DH, Wang TN, Hu X, Rothman V, Tuszynski GP. Thrombospondin-1 and transforming growth factor-beta 1 promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. Surgery 1997;122: 493-499; discussion 499-500.
10. Krishnamurti C, Alving B. Plasminogen activator inhibitor type 1: Biochemistry and evidence for modulation of fibrinolysis in vivo. Semin Thromb Hemost 1992;18:67-80.
11. Bianchi E, Cohen RL, Dai A, Thor AT, Shuman MA, Smith HS. Immunohistochemical localization of the plasminogen activator inhibitor 1 in breast cancer. Int J Cancer 1995;60: 597-603.
12. Seiffert D, Ciambrone G, Wagner NV, Binder BR, Loskutoff DJ. The somatomedin B domain of vitronectin. Structural requirements For the binding and stabilization of active type I plasminogen activator inhibitor. J Biol Chem 1994;269:2659-2666.
13. Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG. Combined over-expression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: An immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer 1996;77:1079-1088.
14. Grondahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK, Brunner N. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 1997;43: 153-163.
15. Flaumenhaft R, Rifkin DB. Extracellular matrix regulation of growth factor and protease activity [review]. Curr Opin Cell Biol 1991;3:817-823.
16. Flaumenhaft R, Rifkin DB. The extracellular regulation of growth factor action [review]. Mol Biol Cell 1992;3:1057-1065.
17. Tuszynski GP, Nicosia RF. Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma. Lab Invest 1994;70: 228-233.
18. Clezardin P, Frappart L, Clerget M, Pechoux C, Delmas PD. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res 1993;53:1421-1430.
19. Arnoletti J, Albo D, Granick MS, Soloman MP, Castiglioni A, Rothman VL, Tuszynski GP. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer 1995;76:998-1005.
20. Tuszynski GP. The role of thrombospondin in malignancy and tumor cell metastasis. In Lahav J, ed. Thrombospondin. Boca Raton: CRC Press, 1993, pp 209-225.
21. Wang TN, Qian XH, Granick MS, Solomon MP, Rothman VL, Berger DH, Tuszynski GP. Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor. Surgery 1996;120:449-454.
22. Tuszynski GP, Smith M, Rothman VL, Capuzzi DM, Joseph RR, Katz J, Besa EC, Treat J, Switalska HI. Thrombospondin levels in patients with malignancy. Thromb Haemost 1992;67: 607-611.
23. Tuszynski GP, Rothman VL, Papale M, Hamilton BK, Eyal J. Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain. J Cell Biol 1993;120:513-521.
24. Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis. Cancer Res 1989;49:2533-2553.
25. Keski-Oja J, Koli K, Lohi L, Laiho M. Growth factors in the regulation of the plasminogen plasmin-system in tumor cells. Semin Thromb Hemost 1991;17:231-239.
26. Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism. J Cell Biol 1993;122:923-932.
27. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-β in a chemically defined system. J Biol Chem 1994;269:26775-26782.
28. Schultz-Cherry S, Lawler J, Murphy-Ullrich JE. The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-β. J Biol Chem 1994;269:26783-26788.
29. Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Kratzsch HC, Roberts DD, Murphy-Ullrich JE. Regulation of transforming growth factor-β activation by discrete sequences of thrombospondin 1. J Biol Chem 1995;270:7304-7310.
30. Tuszynski GP, Srivastava S, Switalska HI, Holt JC, Cierniewski CS, Niewiarowski S. The interaction of human platelet thrombospondin with fibrinogen. J Biol Chem 1985; 260:12240-12245.
31. Wang TN, Qian X, Granick MS, Solomon MP, Rothman VL, Berger DH, Tuszynski GP. Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res 1996;63:39-43.
32. Jakowlew SB, Mariano JM, You L, Mathias A. Differential regulation of protease and extracellular matrix protein expression by transforming growth factor-beta 1 in non-small cell lung cancer cells and normal human bronchial epithelial cells. Biochim Biophys Acta 1997;1353:157-170.
33. Jakowlew SB, Mariano JM, You L. Effects of transforming growth factor-beta 1 and phorbol ester on PAI-1 and PA genes in human lung cells. Growth Factors 1997;14:177-197.
34. van Waarde MA, van Assen AJ, Kanpinga HH, Konings AW, Vujaskovicz Z. Quantification of transforming growth factor-beta in biological material using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1997;247:45-51.
35. Mohanam S, Sawaya RE, Yamamoto M, Bruner JM, Nicholson GL, Rao JS. Proteolysis and invasiveness of brain tumors: Role of urokinase-type plasminogen activator receptor. J Neurooncol 1994;22:153-160.
36. Albo D, Berger DH, Tuszynski GP. The effect of Thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion. J Surg Res 1998;76:86-90.
37. Berger D, Jardines L, Chang H, Ruggieri B. Activation of Raf-1 in human pancreatic adenocarcinoma. J Surg Res 1997; 69:199-204.
38. Grondal-Hansen J, Ralfkiaer E, Kirkeby LT, Kristensen P, Lund LR, Dano K. Localization of urokinase type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 1991;138:111-117.
39. Pyke C, Kristensen P, Ralfkiaer E, Grondal-Hansen J, Eriksen J, Blassi F, Dano K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138:1059-1067.
40. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Blassi F, Dano K. The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the stroma. Cancer Res 1991;51:4067-4071.